Close

 

In 2015, Domain Therapeutics and Dominique Bagnard, Gérard Crémel and Pierre Hubert, three academic researchers from the university of Strasbourg co-founded PeptiMimesis. This new entity was fully dedicated to complete and further develop a transmembrane peptide technology and exploit this breakthrough approach in oncology. PeptiMimesis was supported by Cap Innov’Est, a regionally-based seed fund and the French national Bank of investments Bpifrance. In 2020, PeptiMimesis transferred its intellectual property to a new company specifically incorporated to design and develop membrane allosteric peptides (MAPs) targeting GPCRs for rare diseases.

Program description

undisclosed targets

  • Discovery
  • Candidate
  • Preclinical
  • Clinical

Conventional drug candidates developed against membrane receptors essentially binds to extracellular or intracellular part of the targeted proteins. Transmembrane peptides are able to interfere with the transmembrane domain of receptors to modulate the receptor pharmacology. Such compounds constitute the next generation of allosteric modulators and biased ligands of GPCRs.

Other Programs

PAR2 negative allosteric modulator for rare inflammatory diseases

Discover

Sema3A fusion protein for immuno-oncology

Discover